Relationship between cell adhesion molecule CD99 and tumor: Recent progress

Academic Journal of Second Military Medical University

Volumn 30, Issue 3, 2009, Pages 313-316

  Lin, Li Ping ^a   Wu, Qi ^b   Cao, Guang Wen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD99; Gene; Neoplasms

Indexed keywords

CD99 ANTIGEN;

APOPTOSIS; CANCER INFILTRATION; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; DIFFERENTIAL DIAGNOSIS; HUMAN; METASTASIS POTENTIAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR; TUMOR CELL; TUMOR GROWTH;

EID: 63249111777     PISSN: 0258879X     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1008.2009.00313     Document Type: Review

References (36)

1. Chinese source.
2. Ellis N A, Ye T Z, Patton S, German J, Goodfellow P N, Weller P. Cloning of PBDX, an MIC2-related gene that spans the pseudoautosomal boundary on chromosome Xp[J]. Nat Genet, 1994, 6: 394-400.
3. Banting G S, Pym B, Darling S M, Goodfellow P N. The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein[J]. Mol Immunol, 1989, 26: 181-188.
4. Hahn J H, Kim M K, Choi E Y, Kim S H, Sohn H W, Ham D I, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion[J]. J Immunol, 1997, 159: 2250-2258.
5. + thymocytes[J]. J Immunol, 1995, 154: 26-32.
6. Bernard G, Raimondi V, Alberti I, Pourtein M, Widjenes J, Ticchioni M, et al. CD99 (E2) up-regulates alpha 4 beta 1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions[J]. Eur J Immunol, 2000, 30: 3061-3065.
7. Sohn H W, Shin Y K, Lee I S, Bae Y M, Suh Y H, Kim M K, et al. CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface[J]. J Immunol, 2001, 166: 787-794.
8. Choi E Y, Park W S, Jung K C, Kim S H, Kim Y Y, Lee W J, et al. Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes [J]. J Immunol, 1998, 161: 749-754.
9. Lee E J, Lee H G, Park S H, Choi E Y, Park S H. CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells[J]. Exp Mol Med, 2003, 35: 438-447.
10. Perlman E J, Dickman P S, Askin F B, Grier H E, Miser J S, Link M P. Ewing' s sarcoma - routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study[J]. Hum Pathol, 1994, 25: 304-307.
11. Chinese source.
12. van de Rijn M, Barr F G, Xiong Q B, Hedges M, Shipley J, Fisher C. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features[J]. Am J Surg Pathol, 1999, 23: 106-112.
13. Folpe A L, Patterson K, Gown A M. Antibodies to desmin identify the blastemal component of nephroblastoma [J]. Mod Pathol, 1997, 10: 895-900.
14. Mhawech-Fauceglia P, Herrmann F, Penetrante R, Beck A, Sait S, Block A M, et al. Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies[J]. Histopathology, 2006, 49: 569-575.
15. Scotlandi K, Baldini N, Cerisano V, Manara M C, Benini S, Serra M, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors[J]. Cancer Res, 2000, 60: 5134-5142.
16. Soslow R A, Bhargava V, Warnke R A. MIC2, TdT, bcl-2, and CD34 expression in paraffin embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities[J]. Hum Pathol, 1997, 28: 1158-1165.
17. Chinese source.
18. Lee I, Kim M K, Choi E Y, Mehl A, Jung K C, Gil M C, et al. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB[J]. Blood, 2001, 97: 3596-3604.
19. Tzankov A, Bourgau C, Kaiser A, Zimpfer A, Maurer R, Pileri S A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma[J]. Mod Pathol, 2005, 18: 1542-1549.
20. Chan W C. The Reed-Sternberg cell in classical Hodgkin's disease [J]. Hematol Oncol, 2001, 19: 1-17.
21. Kim S H, Shin Y K, Lee I S, Bae Y M, Sohn H W, Suh Y H, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype[J]. Blood, 2000, 95: 294-300.
22. Lee I S, Shin Y K, Chung D H, Park S H. LMP1-induced down-regulation of CD99 molecules in Hodgkin and Reed-Sternberg cells[J]. Leuk Lymphoma, 2001, 42: 587-594.
23. Suh Y H, Kim M K, Shin Y K, Kim S H, Oh K I, Gil M, et al. Mutations of the immunoglobulin heavy chain variable region gene in CD99-deficient BJAB cell line[J]. Mol Cells, 2002, 13: 237-244.
24. Chinese source.
25. Lee J H, Kim S H, Wang L H, Choi Y L, Kim Y C, Kim J H, et al. Clinical significance of CD99 down-regulation in gastric adenocarcinoma [J]. Clin Cancer Res, 2007, 13: 2584-2591.
26. Jung K C, Park W S, Bae Y M, Hahn J H, Hahn K, Lee H, et al. Immunoreactivity of CD99 in stomach cancer[J]. J Korean Med Sci, 2002, 17: 483-489.
27. Kim E, Lee H J, Hahn J H, Park S H, Lee H. Expression of a spliced variant of CD99 membrane protein increases motility, matrix degradation, and invasiveness of human breast carcinoma cells[J]. Proc Amer Assoc Cancer Res, 2000, 41: 231-232.
28. Stetler-Stevenson W G, Yu A E. Proteases in invasion: matrix metalloproteinases[J]. Semin Cancer Biol, 2001, 11: 143-152.
29. Scotlandi K, Zuntini M, Manara M C, Sciandra M, Rocchi A, Benini S, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity[J]. Oncogene, 2007, 26: 6604-6618.
30. Lee H J, Kim E, Jee B, Hahn J H, Han K, Jung K C, et al. Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells[J]. Exp Mol Med, 2002, 34: 177-183.
31. Zhou J H, Ye F, Chen H Z, Zhou C Y, Lu W G, Xie X. Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma[J]. Life Sci, 2006, 78: 2643-2649.
32. Kim H S, Kim J S, Kim J S, Park J T, Lee M C, Juhng S W, et al. The association between CD99 and LMP-1 expression in nasopharyngeal carcinoma[J]. Exp Oncol, 2006, 28: 40-43.
33. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs) [J]. Histopathology, 2004, 45: 384-392.
34. Vasdev N, Nayak N C. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour[J]. Indian J Pathol Microbiol, 2003, 46: 625-629.
35. Chinese source.
36. Perlman E J, Lumadue J A, Hawkins A L, Cohen K, Colombani P, Griffin C A. Primary cutaneous neuroendocrine tumors. Diagnostic use of cytogenetic and MIC2 analysis[J]. Cancer Genet Cytogenet, 1995, 82: 30-34.